The FDA Desk — 2026-05-19

TITLE: FDA Desk — May 19: Wells Pharma fentanyl/ketamine sweep, ophthalmic sterility cluster widens

---

Lead

No Class I actions posted today. All ten enforcement entries are Class II, firm-initiated voluntary recalls, but they cluster into two regulatorily significant themes: (1) a multi-product cGMP action against a Houston compounder of controlled-substance injectables, and (2) a continuing sterility-assurance sweep across over-the-counter ophthalmic lubricants flagged during FDA facility inspections.

Compounded controlled-substance injectables — Wells Pharma of Houston

Five Class II recalls (D-0503-2026, D-0504-2026, D-0505-2026, D-0506-2026, D-0507-2026), all dated 2026-04-01 and all attributed to unspecified "cGMP deviations," cover Wells Pharma of Houston LLC's compounded narcotic injectables. The affected lots span the firm's fentanyl Citrate injectable line in 0.9% Sodium Chloride — 1000 mcg/100 mL (NDC 73702-202-02), 2500 mcg/250 mL (NDC 73702-202-03), 1000 mcg/50 mL (NDC 73702-203-65), and 1250 mcg/25 mL (NDC 73702-204-25) — together with Ketamine Hydrochloride Injection 50 mg/mL (NDC 73702-302-31). The breadth of the action across both Schedule II analgesics and a Schedule III dissociative, with a single common deviation rationale and a single removal date, points to a facility-level quality-system finding rather than a lot-specific defect, and hospital pharmacies should expect downstream sourcing pressure on compounded fentanyl drips.

Ophthalmic sterility cluster — three sponsors, common FDA inspection trigger

Four Class II recalls remove sterile OTC eye products from distribution after FDA inspections raised sterility-assurance concerns at the contract manufacturer level. The recalls are not linked to confirmed contamination but to inspectional findings that, under 21 CFR 211, undermine the firms' ability to assure sterility of distributed lots.

• D-0500-2026 and D-0501-2026 cover Thea Pharma, Inc.'s iVIZIA Sterile Lubricant Eye Drops (Povidone 0.5%), 10 mL, made in France and distributed from Waltham, MA under NDCs 82584-700-11 and 59262-700-11 (the latter co-branded Similasan); both were initiated 2026-04-23 for lack of assurance of sterility tied to CGMP deviations observed during an FDA inspection of the manufacturer.
• D-0492-2026 removes Alcon Research LLC's GenTeal Tears Lubricant Eye Gel, 10 g (NDC 0065-8064-01), distributed by Alcon Laboratories of Fort Worth, after FDA inspection observations the firm "believes may impact product quality" (initiated 2026-04-21).
• D-0499-2026 covers Scope Health Inc.'s Optase Dry Eye Intense Drops (Glycerin 0.2%), 0.33 fl oz (NDC 72972-002-01), recalled 2026-04-20 for lack of assurance of sterility.

The temporal clustering (April 20–23) and the consistent "inspection-driven sterility assurance" language across three unrelated sponsors suggests a common upstream facility or a coordinated FDA enforcement posture toward sterile ophthalmic contract manufacturing — a pattern worth watching for additional Class II expansions in coming weeks.

Other pharmaceutical actions

• D-0526-2026 — Hikma Pharmaceuticals USA Inc. initiated a Class II recall on 2026-04-07 of Alendronate Sodium Oral Solution, 70 mg/75 mL (NDC 0054-0282-59, 4×75 mL single-dose bottles), after out-of-specification assay results in a limited number of bottles stored on their side, indicating a possible container-orientation stability or leakage issue rather than a manufacturing-wide defect.

Editor's note

All ten items today are Class II, meaning use may cause temporary or medically reversible adverse health consequences with a remote probability of serious harm. None require the immediate clinical hold posture associated with Class I. However, the Wells Pharma cluster has practical supply implications for hospital pharmacy controlled-substance inventories, and the ophthalmic sterility cluster should prompt sponsors using shared sterile-fill contract manufacturers to review their own inspection exposure.